Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

T-DM1

National Institute for Health and Care Excellence NICE logo

NICE to update ovarian cancer drug guidelines

Draft guidance backs paclitaxel and Janssen’s Caelyx but not gemcitabine, topetecan or trabectedin

- PMLiVE

Mixed news for Lilly on cancer hope ramucirumab

Fails in phase III for breast cancer but better results for stomach cancer

- PMLiVE

Boehringer’s oncology unit scores first EU approval

Giotrif given green light for non-small cell lung cancer

Roche - Basel

Roche’s Kadcyla and Bayer’s Xofigo near EU approval

Cancer drugs receive CHMP backing

Roche Basel Switzerland

Roche: Keep Cancer Drugs Fund until VBP shown to work

Company says uncertainty remains about impact of new UK pricing system

- PMLiVE

Pharma firms ramp up Cancer Drugs Fund pressure

Novartis, Roche and Sanofi join forces to highlight public attitudes to medicines access

- PMLiVE

Boehringer to work with Roche on cancer diagnostics

Will collaborate with Roche subsidiary Ventana Medical Systems

- PMLiVE

Dendreon’s cancer vaccine wins EU approval

Provenge approved for use in prostate cancer three years after US recommendation

- PMLiVE

Eisai expands in Europe with new Belgium business

Will coordinate local reimbursement for cancer drug Halaven

- PMLiVE

Eisai launches Halaven in Russia

Expands market reach of its breast cancer drug to cover emerging market

- PMLiVE

Lufthansa CEO nominated Roche chairman

Christoph Franz to succeed Franz Humer in 2014

- PMLiVE

Personalised understanding: oncology and orphan diseases

Improvements in our understanding of cancer are drawing the orphan drug and oncology worlds ever closer together

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links